POPULATION MODEL CONFIRMS PREDICTABLE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILE FOR APRAGLUTIDE - DATA FROM TWO RANDOMIZED PHASE 1 STUDIES

被引：0
|
作者：
Bolognani, Federico
Machacek, Matthias
Kruithof, Annelieke
de Kam, Marieke L.
Bergmann, Kirsten
van Gent, Max
Moerland, Matthijs
Crenn, Pascal
Greig, Christian Meyer Gerard
Gal, Pim
Schulthess, Pascal
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su559
引用
收藏
页码：S738 / S738
页数：1
相关论文
共 50 条
  • [1] Population Model Confirms Predictable Pharmacokinetic (PK) And Pharmacodynamic (PD) Profile for Apraglutide: Data From Two Randomized Phase 1 Studies
    Bolognani, Federico
    Machacek, Matthias
    Kruithof, Annelieke
    de Kam, Marieke
    Bergmann, Kirsten
    van Gent, Max
    Moerland, Matthias
    Crenn, Pascal
    Meyer, Christian
    Greig, Gerard
    Gal, Pim
    Schulthess, Pascal
    [J]. TRANSPLANTATION, 2022, 106 (09) : S544 - S544
  • [2] Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients.
    Li, J
    Karlsson, MO
    Brahmer, J
    Cusatis, G
    Hidalgo, M
    Baker, SD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 212S - 212S
  • [3] Pharmacokinetic/pharmacodynamic (PK/PD) population model linking cortisol production with fluticasone concentration.
    Mishina, EV
    Miller, R
    Salcoz, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 201 - 201
  • [4] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH1.
    Danson, S
    Johnson, P
    Ward, T
    Dawson, M
    Denneny, O
    Cummings, J
    Jowle, D
    Howard, E
    Dive, C
    Ranson, M
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9150S - 9150S
  • [5] Establishment of a fexofenadine population pharmacokinetic (PK)-pharmacodynamic (PD) model and exploration of dosing regimens through simulation
    Jang, Ji-Hun
    Jeong, Seung-Hyun
    Lee, Yong-Bok
    [J]. JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 53 (03) : 427 - 441
  • [6] Establishment of a fexofenadine population pharmacokinetic (PK)–pharmacodynamic (PD) model and exploration of dosing regimens through simulation
    Ji-Hun Jang
    Seung-Hyun Jeong
    Yong-Bok Lee
    [J]. Journal of Pharmaceutical Investigation, 2023, 53 : 427 - 441
  • [7] POPULATION PHARMACOKINETIC (PK) AND PHARMACOKINETIC-PHARMACODYNAMIC (PK/PD) ASSESSMENT OF GDC-0334 (A TRPA1 INHIBITOR) IN HEALTHY SUBJECTS.
    Chan, H.
    Li, H.
    Liu, L.
    Ding, H.
    Ferl, G.
    Bauer, R.
    Gao, S.
    Joseph, V.
    Yang, X.
    Quartino, A.
    Putnam, W.
    Pan, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S98 - S98
  • [8] Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
    Michael Boettcher
    Stephanie Loewen
    Mireille Gerrits
    Corina Becker
    [J]. Clinical Pharmacokinetics, 2021, 60 : 337 - 351
  • [9] Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
    Boettcher, Michael
    Loewen, Stephanie
    Gerrits, Mireille
    Becker, Corina
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (03) : 337 - 351
  • [10] Pharmacokinetic and Pharmacodynamic Profile of PEGylated Interferon Beta-1a in Healthy Volunteers: Results from Two Phase 1 Clinical Studies
    Hu, Xiao
    Subramanyam, Meena
    Lerner, Michaela
    Miller, Larisa
    Nestorov, Ivan
    Davar, Gudarz
    [J]. NEUROLOGY, 2009, 72 (11) : A316 - A317
12345